Samsung, SK hynix to build HBM fabs in Chungcheong region

In parallel, the nation's pharmaceutical industry has achieved a landmark success, with exports exceeding $10 billion for the first time in 2025. This record-breaking performance was fueled by strong demand for biopharmaceuticals and the country's growing expertise in contract development and manufacturing. The dual advancements highlight South Korea's expanding role in critical global supply chains for both cutting-edge technology and essential medicines.

The HBM investment by Samsung and SK hynix is particularly crucial for the burgeoning AI sector, as HBM is a key component for high-performance computing required by AI applications. The establishment of new fabs and packaging facilities in the Chungcheong region is expected to create a robust ecosystem for AI chip production within South Korea. Meanwhile, the pharmaceutical export surge underscores the nation's increasing competitiveness in the global life sciences market, driven by innovation and specialized manufacturing services.